Patents Examined by S. Devi
  • Adenovirus vectors
    Patent number: 9017696
    Abstract: An adenoviral vector comprising a promoter further comprising a fragment of the 5? untranslated region of the CMV IE1 gene including intron A and a nucleic acid sequence encoding a pathogen or tumor antigen for use as a medicament.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: April 28, 2015
    Assignee: Isis Innovation Limited
    Inventors: Simon Draper, Arturo Reyes, Saranya Sridhar, Adrian Hill, Sarah Gilbert, Anna Goodman
  • preparations and the treatment of autoimmune conditions
    Patent number: 9005603
    Abstract: This document provides methods and materials related to Prevotella histicola preparations. For example, Prevotella histicola preparations in the form of an oral medicament or dietary supplement (e.g., a pill, tablet, capsule) are provided. In addition, methods and materials for using a Prevotella histicola preparation provided herein as an anti-inflammatory agent are provided.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: April 14, 2015
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Joseph A. Murray, Eric V. Marietta, Susan H. Barton, Veena Taneja, Ashutosh Mangalam
  • Multivalent meningococcal polysaccharide-protein conjugate vaccine
    Patent number: 8999354
    Abstract: The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of four distinct polysaccharide-protein conjugates that are formulated as a single dose of vaccine. Purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y are chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains in children as well as adults.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: April 7, 2015
    Assignee: Sanofi Pasteur Inc.
    Inventor: Robert P. Ryall
  • Antagonists for the prevention or treatment of inflammatory bowel disease, and more particularly of Crohn's disease
    Patent number: 8974789
    Abstract: An antagonist of the interaction between the Gp96 receptor and E. coli AIEC strains, for the prevention or treatment of inflammatory bowel disease. The antagonist is for specifically blocking or reducing the interaction between Gp96 receptor and the outer membrane vesicles (OMVs), typically the outer protein membrane OmpA of E. coli AIEC strains. The inventions provides for pharmaceutical compositions containing such an antagonist, which may be an antibody against gp96 or OmpA, or a gp96 or OmpA polypeptide. It may be combined to an antagonist of the interaction between the CEACAM6 receptor and E. coli AIEC strains, such as an anti-CEACAM6 antibody, a CEACAM6 polypeptide, or a mannoside or particle having a mannose unit. The invention also relates to a method for the diagnosis of inflammatory bowel disease, or of the determination of a predisposition of a person to develop inflammatory bowel disease.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: March 10, 2015
    Assignee: Universite d'Auvergne Clermont I
    Inventors: Arlette Darfeuille-Michaud, Paul Hofman, Nathalie Rolhion
  • GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by
    Patent number: 8968748
    Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
    Type: Grant
    Filed: October 21, 2011
    Date of Patent: March 3, 2015
    Assignee: Children's Hospital & Research Center Oakland
    Inventors: Dan M. Granoff, Victor Chen-Hsi Hou
  • Immunogenic compositions for
    Patent number: 8945589
    Abstract: This application relates to Group B Streptococcus (“GBS”) vaccines comprising combinations of GBS polypeptide antigens where the polypeptides contribute to the immunological response in a recipient. Preferably, the compositions of the invention comprise a combination of two or more GBS antigens, wherein said combination includes GBS 80 or a fragment thereof. In one embodiment, the combination may consist of two to thirteen GBS antigens selected from an antigen group consisting of GBS 80, GBS 91, GBS 104, GBS 184, GBS 276, GBS 305, GBS 322, GBS 330, GBS 338, GBS 361, GBS 404, GBS 690, and GBS 691.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: February 3, 2015
    Assignee: Novartis Vaccines and Diagnostics, SRL
    Inventors: John Telford, Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione
  • Use of for treatment of autoimmune diseases
    Patent number: 8936783
    Abstract: The present technology relates to the use of at least one strain of probiotic bacteria selected from Lactobacillus for the manufacture of a medicament for the treatment and/or prevention of an autoimmune disease.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: January 20, 2015
    Assignee: Probi AB
    Inventors: Jan Alenfall, Anna Berggren, Carola Rask, Agnes Wold, Shahram Aghaibeik-Lavasani
  • Flagellin related polypeptides and uses thereof
    Patent number: 8932609
    Abstract: The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptosis is described.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: January 13, 2015
    Assignee: Cleveland Clinic Foundation
    Inventors: Andrei V. Gudkov, Joseph A. DiDonato, Vadim Krivokrysenko
  • Conjugation process for PNAG and a carrier protein
    Patent number: 8933218
    Abstract: The present application describes a process for conjugating a PNAG which is less than 40% N-acetylated to a carrier protein.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: January 13, 2015
    Assignee: GlaxoSmithKline Biologicals s.a.
    Inventors: Ralph Leon Biemans, Pierre Duvivier, Tomas Maira-Litran
  • Vaccine
    Patent number: 8926985
    Abstract: The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein D from H. influenzae.
    Type: Grant
    Filed: November 5, 2009
    Date of Patent: January 6, 2015
    Assignee: GlaxoSmithKline Biologicals S A
    Inventors: Carine Capiau, Marguerite Deschamps, Pierre Michel Desmons, Craig Antonyjoseph Laferriere, Jan Poolman, Jean-Paul Prieels
  • Compositions and methods for screening for Lyme disease
    Patent number: 8926989
    Abstract: The invention provides compositions, methods, and kits for the diagnosis or detection of infection by a pathogen that causes Lyme disease in a subject.
    Type: Grant
    Filed: March 10, 2011
    Date of Patent: January 6, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Burbelo, Adriana Marques, Michael J. Iadarola
  • Treatment and diagnosis of inflammatory disorders and HIV
    Patent number: 8926990
    Abstract: This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: January 6, 2015
    Assignee: Rutgers, The State University of New Jersey
    Inventor: Scott C. Kachlany
  • Cholera toxin chimera and its use as a staph vaccine
    Patent number: 8911748
    Abstract: The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: December 16, 2014
    Assignee: Boise State University
    Inventor: Juliette Tinker
  • Compositions and methods for vaccinating cattle
    Patent number: 8895029
    Abstract: The present invention relates to compositions, uses thereof, and methods of vaccinating cattle, particularly cows and heifers, against Leptospira borgpetersenii serovar hardjo (type hardjo-bovis) by using Leptospira interrogans serovar hardjo (type hardjoprajitno).
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: November 25, 2014
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventor: Carol L. Rinehart
  • Flagellin related polypeptides and uses thereof
    Patent number: 8871215
    Abstract: The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptsis is described.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: October 28, 2014
    Assignee: Cleveland Clinic Foundation
    Inventors: Andrei V. Gudkov, Joseph A. DiDonato, Vadim Krivokrysenko
  • Process for manufacturing vaccines
    Patent number: 8858955
    Abstract: The present application discloses a method for making an immunogenic composition comprising an improved way of conducting saccharide-protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. In addition, the conjugate is mixed with a staphylococcal antigen. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.
    Type: Grant
    Filed: January 2, 2008
    Date of Patent: October 14, 2014
    Assignee: GlaxoSmithKline Biologicals s.a.
    Inventors: Ralph Leon Biemans, Pierre Duvivier
  • Live attenuated bacterial vaccine to reduce or inhibit carriage and shedding of enterohemorrhagic in cattle
    Patent number: 8858930
    Abstract: The invention provides live, attenuated enterohemorrhagic Escherichia coli (EHEC) bacteria in which the Shiga toxin coding sequences are deleted to abolish Shiga toxin production and one or more of the nucleotide sequences for the bacterial adhesin protein intimin, the locus of enterocyte effacement encoded regulator, and the translocated intimin receptor are mutated to inactivate the activity of the encoded protein(s). This live, attenuated E. coli bacteria is used in a vaccine for reducing or inhibiting carriage and shedding of EHEC in cattle.
    Type: Grant
    Filed: October 26, 2005
    Date of Patent: October 14, 2014
    Assignees: The United States of America as Represented by the Department of Veteran Affairs
    Inventors: Chengru Zhu, Edgar Boedeker
  • GAS57 mutant antigens and GAS57 antibodies
    Patent number: 8858957
    Abstract: The invention provides mutants of GAS57 (Spy0416) which are unable to cleave IL-8 and similar substrates but which still maintain the ability to induce protection against S. pyogenes. The invention also provides antibodies which specifically bind to GAS57 and which inhibit its ability to cleave IL-8 and similar substrates. The mutants are useful, inter alia, in vaccine compositions to induce protection against S. pyogenes. The antibodies are useful, e.g., as therapeutics for treating S. pyogenes infections.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: October 14, 2014
    Assignee: Novartis AG
    Inventors: Immaculada Margarit Y Ros, Guido Grandi, Chiara Zingaretti
  • Cholera toxin chimera and its use as a staph vaccine
    Patent number: 8834898
    Abstract: The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: September 16, 2014
    Assignee: Boise State University
    Inventor: Juliette Tinker
  • Adjuvanted meningococcus compositions
    Patent number: RE45137
    Abstract: A combination of CpG oligonucleotides and polymer microparticles is an extremely effective adjuvant for Neisserial antigens. The invention therefore provides a composition comprising: (a) a Neisserial antigen; (b) a CpG oligonucleotide; and (c) a biodegradable polymer microparticle.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: September 16, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Nicholas Valiante